Literature DB >> 7803632

Clinically significant mucosal candidiasis resistant to fluconazole treatment in patients with AIDS.

S L Newman1, T P Flanigan, A Fisher, M G Rinaldi, M Stein, K Vigilante.   

Abstract

Eight cases of severe mucosal candidiasis in patients with AIDS who were taking fluconazole at a dosage of 400-800 mg/d are described. Candida albicans alone or in conjunction with Torulopsis glabrata or Candida stellatoidea was isolated from each patient. In vitro susceptibility testing demonstrated resistance to fluconazole in all eight cases. All tested isolates were susceptible to amphotericin B, and six of eight isolates tested were susceptible to itraconazole. All individuals were severely immunocompromised (CD4 lymphocyte counts: mean, 15/mm3; range, 6-39/mm3) and had been receiving prophylaxis with fluconazole for a mean of only 3 months (range, 1-7 months). The occurrence of candidal mucositis in patients receiving high doses of fluconazole is a matter of concern that requires further study in regard to the causes, prevention, and treatment of the disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7803632     DOI: 10.1093/clinids/19.4.684

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  27 in total

Review 1.  Antifungal prophylaxis during neutropenia and immunodeficiency.

Authors:  O Lortholary; B Dupont
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

2.  Treatment of murine disseminated candidiasis with L-743,872.

Authors:  J R Graybill; L K Najvar; M F Luther; A W Fothergill
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

3.  Rapid identification of Candida species in oral rinse solutions by PCR.

Authors:  Giorgio Liguori; Angela Lucariello; Giuseppe Colella; Antonio De Luca; Paolo Marinelli
Journal:  J Clin Pathol       Date:  2007-09       Impact factor: 3.411

Review 4.  Susceptibility testing of fungi: current status of correlation of in vitro data with clinical outcome.

Authors:  M A Ghannoum; J H Rex; J N Galgiani
Journal:  J Clin Microbiol       Date:  1996-03       Impact factor: 5.948

5.  Pharmacokinetics of fluconazole in saliva and plasma after administration of an oral suspension and capsules.

Authors:  C H Koks; P L Meenhorst; M J Hillebrand; A Bult; J H Beijnen
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

6.  Thirteen-year evolution of azole resistance in yeast isolates and prevalence of resistant strains carried by cancer patients at a large medical center.

Authors:  C R Boschman; U R Bodnar; M A Tornatore; A A Obias; G A Noskin; K Englund; M A Postelnick; T Suriano; L R Peterson
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

7.  Susceptibilities of oral bacteria and yeast to mammalian cathelicidins.

Authors:  J M Guthmiller; K G Vargas; R Srikantha; L L Schomberg; P L Weistroffer; P B McCray; B F Tack
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

8.  Molecular epidemiology of Candida isolates from AIDS patients showing different fluconazole resistance profiles.

Authors:  A Lischewski; M Ruhnke; I Tennagen; G Schönian; J Morschhäuser; J Hacker
Journal:  J Clin Microbiol       Date:  1995-03       Impact factor: 5.948

9.  Correlation between in vitro resistance to fluconazole and clinical outcome of oropharyngeal candidiasis in HIV-infected patients.

Authors:  C Quereda; A M Polanco; C Giner; A Sánchez-Sousa; E Pereira; E Navas; J Fortún; A Guerrero; F Baquero
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-01       Impact factor: 3.267

10.  Response to fluconazole by 23 patients with human immunodeficiency virus infection and oral candidiasis: pharmacological and mycological factors.

Authors:  F Lacassin; F Damond; C Chochillon; P Longuet; J Lebras; J L Vilde; C Leport
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.